2. Academic Validation
  3. Discovery of a highly orally bioavailable c-5-[6-(4-Methanesulfonyloxyphenyl)hexyl]-2-methyl-1,3-dioxane-r-2-carboxylic acid as a potent hypoglycemic and hypolipidemic agent

Discovery of a highly orally bioavailable c-5-[6-(4-Methanesulfonyloxyphenyl)hexyl]-2-methyl-1,3-dioxane-r-2-carboxylic acid as a potent hypoglycemic and hypolipidemic agent

  • Bioorg Med Chem Lett. 2008 Oct 15;18(20):5586-90. doi: 10.1016/j.bmcl.2008.08.112.
Harikishore Pingali 1,  Mukul Jain,  Shailesh Shah,  Sujay Basu,  Pankaj Makadia,  Amitgiri Goswami,  Pandurang Zaware,  Pravin Patil,  Atul Godha,  Suresh Giri,  Ashish Goel,  Megha Patel,  Harilal Patel,  Pankaj Patel
Affiliations

Affiliation

  • 1 Zydus Research Centre, Sarkhej-Bavla N.H 8A Moraiya, Ahmedabad 382210, India.
PMID: 18805005 DOI: 10.1016/j.bmcl.2008.08.112
Abstract

A series of novel 1,3-dioxane-2-carboxylic acid derivatives containing alkyl chain tether and substituted phenyl group as a lipophilic tail have been prepared as agonists of PPARalpha and gamma. c-5-[6-(4-Methanesulfonyloxyphenyl)hexyl]-2-methyl-1,3-dioxane-r-2-carboxylic acid 13c exhibited potent hypoglycemic and lipid lowering activity with high oral bioavailability in animal models.

Figures